Mensa, JBarberán, JFerrer, RBorges, MRascado, PMaseda, EOliver, AMarco, FAdalia, RAguilar, GEstella, ALeón López, RRobles Marcos, M SGonzález de Molina, F JSerrano García, RSalavert, MFernández Gómez, JPoliakova, YPasquau, JAzanza, J RBou Arévalo, GLLinares Mondéjar, PCardinal-Fernández, PSoriano, A2025-01-072025-01-072021-10-25https://hdl.handle.net/10668/25096Severe infection and its evolution to sepsis are becoming more prevalent every day and are among the leading causes of critical illness and mortality. Proper management is crucial to improve prognosis. This document addresses three essential points that have a significant impact on this objective: a) early recognition of patients with sepsis criteria, b) identification of those patients who suffer from an infection and have a high risk of progressing to sepsis, and c) adequate selection and optimization of the initial antimicrobial treatment.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/antimicrobial treatmentceftazidime-avibactamceftolozane-tazobactammeropenemoptimizationsepsisseptic shocksevere infectionAnti-Bacterial AgentsCeftazidimeCephalosporinsCross InfectionHumansTazobactamresearch article34693705open access10.37201/req/126.20211988-9518PMC8638841https://seq.es/wp-content/uploads/2021/10/mensa25oct2021.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8638841/pdf